Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Strefling

Cardiovascular Disease Lubbock, TX Doctor of Osteopathy

NPI 1720215296 CMS profile 1378244

3514 21St St, Lubbock, TX 79410

Open in the dashboard

General payments

$32,713

505 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Strefling of Lubbock, TX is reported in the CMS Open Payments database as having received $32,713 across 505 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,079 52
2024 General $1,809 82
2023 General $1,758 74
2022 General $6,477 94
2021 General $8,950 87
2020 General $10,710 34
2019 General $1,930 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Strefling
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jason Strefling were reported at $1,079. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jason Strefling Cardiovascular Disease median Middle half National median
2019 $1,930 $450 $127–$1,392 $163
2020 $10,710 $242 $77–$751 $114
2021 $8,950 $335 $101–$1,037 $132
2022 $6,477 $395 $121–$1,211 $149
2023 $1,758 $443 $136–$1,283 $160
2024 $1,809 $450 $136–$1,323 $164
2025 $1,079 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $21,724 61 payments
  2. Boston Scientific Corporation $2,056 54 payments
  3. Novartis Pharmaceuticals Corporation $1,602 87 payments
  4. Abbott Laboratories $1,550 24 payments
  5. Medtronic, Inc. $779 42 payments
  6. Shockwave Medical, Inc $559 7 payments
  7. E.R. Squibb & Sons, L.L.C. $456 26 payments
  8. Pfizer Inc. $396 21 payments
  9. Merck Sharp & Dohme Corporation $366 22 payments
  10. Janssen Pharmaceuticals, Inc $330 23 payments
  11. Other $2,894 138 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,950 15 payments
  2. Food and Beverage $12,073 485 payments
  3. Consulting Fee $1,395 1 payment
  4. Education $151 3 payments
  5. Travel and Lodging $144 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $13,855 33 payments
  2. BRILINTA $7,793 22 payments
  3. LEQVIO $637 28 payments
  4. VERQUVO $592 34 payments
  5. ENTRESTO Cardiovascular $553 39 payments
  6. ENTRESTO Cardiology/Vascular Diseases $450 21 payments
  7. XARELTO $330 23 payments
  8. Vascular Lithotripsy $314 3 payments
  9. ELIQUIS $299 20 payments
  10. LifeVest $274 15 payments
  11. Other $8,122 308 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

6,609

Median for Cardiology: 2,533

Drug cost

$895,042

Median for Cardiology: $485,213

Branded share of claims

27.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 410 $380,895
Xarelto Rivaroxaban Brand 136 $111,562
Entresto Sacubitril/Valsartan Brand 91 $88,985
Repatha Sureclick Evolocumab Brand 131 $83,005
Farxiga Dapagliflozin Propanediol Brand 80 $62,954
Multaq Dronedarone Hcl Brand 33 $34,200
Brilinta Ticagrelor Brand 39 $28,327
Ranolazine Er Ranolazine Brand 156 $16,743
Praluent Pen Alirocumab Brand 32 $15,676
Vascepa Icosapent Ethyl Brand 22 $11,562

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$199,979

Of which drugs: $957

Medicare patients

788

Average age 74

Services billed

2,618

410 women, 378 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 46%
Diabetes 39%
Heart failure 34%
Chronic kidney disease 31%
Atrial fibrillation 30%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 37 148 $957

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$238 — —
VERQUVO
$226 — —
ENTRESTO
$185 91 —
FARXIGA
$140 80 —
JARDIANCE
$45 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

505 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record